CN108884127A - 合成的阿片类疫苗 - Google Patents

合成的阿片类疫苗 Download PDF

Info

Publication number
CN108884127A
CN108884127A CN201780007832.8A CN201780007832A CN108884127A CN 108884127 A CN108884127 A CN 108884127A CN 201780007832 A CN201780007832 A CN 201780007832A CN 108884127 A CN108884127 A CN 108884127A
Authority
CN
China
Prior art keywords
fentanyl
vaccine
drug
haptens
class drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780007832.8A
Other languages
English (en)
Chinese (zh)
Inventor
金姆·D·扬达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN108884127A publication Critical patent/CN108884127A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780007832.8A 2016-01-21 2017-01-18 合成的阿片类疫苗 Pending CN108884127A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281262P 2016-01-21 2016-01-21
US62/281,262 2016-01-21
PCT/US2017/013865 WO2017127390A1 (en) 2016-01-21 2017-01-18 Synthetic opioid vaccine

Publications (1)

Publication Number Publication Date
CN108884127A true CN108884127A (zh) 2018-11-23

Family

ID=59362842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780007832.8A Pending CN108884127A (zh) 2016-01-21 2017-01-18 合成的阿片类疫苗

Country Status (7)

Country Link
US (1) US11305010B2 (https=)
EP (1) EP3405475B1 (https=)
JP (1) JP2019506390A (https=)
CN (1) CN108884127A (https=)
BR (1) BR112018014908A2 (https=)
RU (1) RU2018130106A (https=)
WO (1) WO2017127390A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094528A1 (en) 2017-11-09 2019-05-16 The Scripps Research Institute An improved heroin vaccine
WO2020006563A1 (en) * 2018-06-29 2020-01-02 Marquette University Fluorinated compounds as ph-sensitive analgesics
EP4054571A4 (en) * 2019-11-08 2024-01-10 Regents of the University of Minnesota FENTANYL HAPTEN, FENTANYL HAPTEN CONJUGATES, AND METHODS OF MAKING AND USING THE SAME
US20230100186A1 (en) * 2020-01-13 2023-03-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Fentanyl haptens for the preparation of a fentanyl vaccine
WO2021183913A1 (en) * 2020-03-13 2021-09-16 Regents Of The University Of Minnesota Fentanyl haptens, fentanyl hapten conjugates, and methods for making and using
US20240307517A1 (en) * 2021-05-10 2024-09-19 Cornell University Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction
EP4694925A2 (en) * 2023-04-13 2026-02-18 Avicenna Biotech Research, Llc Compositions and methods for treating fentanyl dependence

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
CN1428607A (zh) * 2001-11-16 2003-07-09 兰多克斯实验室有限公司 检测或定量测定芬太尼的代谢物或芬太尼类似物的代谢物的方法和试剂盒
WO2004111202A2 (en) * 2003-03-07 2004-12-23 Incyte Corporation Neurotransmission-association proteins
CN1668331A (zh) * 2002-07-18 2005-09-14 赛托斯生物技术公司 半抗原－载体偶联物及其用途
CN102421789A (zh) * 2009-04-15 2012-04-18 浦项工科大学校产学协力团 靶特异性非抗体蛋白质及其制备方法
US20140093525A1 (en) * 2012-09-17 2014-04-03 Minneapolis Medical Research Foundation Compositions and methods of treating opioid addiction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3941893A (en) 1992-04-06 1993-11-08 Biosite Diagnostics Incorporated Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US6262265B1 (en) 1999-06-18 2001-07-17 Microgenics Corporation Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
WO2006086469A2 (en) * 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
SG10201509499RA (en) * 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
JP2015502356A (ja) * 2011-11-30 2015-01-22 ウェルスタット ダイアグノスティクス，エルエルシー ５−ｆｕに関連するアッセイ、抗体、免疫原および組成物
AU2011383735A1 (en) 2011-12-21 2014-08-14 The Scripps Research Institute Heroin haptens, immunoconjugates and related uses
US9981043B2 (en) 2013-02-08 2018-05-29 Regents Of The University Of Minnesota Analgesic conjugates
US9213029B2 (en) * 2013-06-25 2015-12-15 Samsung Electronics Co., Ltd. Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
CN1428607A (zh) * 2001-11-16 2003-07-09 兰多克斯实验室有限公司 检测或定量测定芬太尼的代谢物或芬太尼类似物的代谢物的方法和试剂盒
CN1668331A (zh) * 2002-07-18 2005-09-14 赛托斯生物技术公司 半抗原－载体偶联物及其用途
WO2004111202A2 (en) * 2003-03-07 2004-12-23 Incyte Corporation Neurotransmission-association proteins
CN102421789A (zh) * 2009-04-15 2012-04-18 浦项工科大学校产学协力团 靶特异性非抗体蛋白质及其制备方法
US20140093525A1 (en) * 2012-09-17 2014-04-03 Minneapolis Medical Research Foundation Compositions and methods of treating opioid addiction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M. MICHIELS等: "A Sensitive Radioimmunoassay for Fentanyl", 《EUROP. J. CLIN. PHARMACOL.》 *
PAUL T. BREMER等: "Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs", 《ANGEW. CHEM.》 *
RUBEN VARDANYAN等: "Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
YAGHOUB HAGHIGHATNIA等: "Designing and Synthesis of Novel Amidated Fentanyl Analogs", 《HELVETICA CHIMICA ACTA》 *
刘雁勇等: "μ受体激动剂芬太尼多克隆抗体的制备", 《放射免疫学杂志》 *

Also Published As

Publication number Publication date
EP3405475B1 (en) 2022-09-28
RU2018130106A3 (https=) 2020-05-26
WO2017127390A1 (en) 2017-07-27
BR112018014908A2 (pt) 2018-12-18
RU2018130106A (ru) 2020-02-21
EP3405475A1 (en) 2018-11-28
EP3405475A4 (en) 2019-08-28
JP2019506390A (ja) 2019-03-07
US11305010B2 (en) 2022-04-19
US20210128720A1 (en) 2021-05-06
CA3015336A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
US11305010B2 (en) Synthetic opioid vaccine
Bremer et al. Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs
Robinson et al. Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity
Moreno et al. Impact of distinct chemical structures for the development of a methamphetamine vaccine
Pravetoni et al. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens
Stowe et al. A vaccine strategy that induces protective immunity against heroin
Shen et al. A vaccine against methamphetamine attenuates its behavioral effects in mice
Hwang et al. Efficacious vaccine against heroin contaminated with fentanyl
Barrientos et al. Novel vaccine that blunts fentanyl effects and sequesters ultrapotent fentanyl analogues
Collins et al. Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse
St. John et al. Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy
Crouse et al. A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models
Park et al. Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin
US20190240306A1 (en) Anti-opioid vaccines
Ramakrishnan et al. Hapten optimization for cocaine vaccine with improved cocaine recognition
AU2017213534B2 (en) Heroin haptens, immunoconjugates and related uses
Lee et al. A vaccine against benzimidazole-derived new psychoactive substances that are more potent than fentanyl
Lin et al. Broadly neutralizing synthetic cannabinoid vaccines
Hosztafi et al. Opioid-based haptens: development of immunotherapy
Kantak Anti-cocaine vaccines: antibody protection against relapse
Zheng et al. Family of structurally related bioconjugates yields antibodies with differential selectivity against ketamine and 6-hydroxynorketamine
CA3015336C (en) Synthetic opioid vaccine
Park et al. Development of a vaccine against the synthetic opioid U-47700
CN102002049B (zh) 一种抗原及其制备方法与应用
Yin et al. A conjugate vaccine strategy that induces protective immunity against arecoline

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123